Acurx Pharmaceuticals, Inc. (ACXP) Key Metrics
ACXP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.1M
- Enterprise value
- −$4.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −2.05
ACXP key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsACXP returns How much profit the business earns on the capital it uses.
ACXP financial health Debt, liquidity and how easily interest is covered.
ACXP valuation history
ACXP returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ACXP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ACXP cash returned to shareholders
ACXP price vs earnings per share
ACXP key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $3.7M | — | — | — | — | — | — |
| Enterprise value | −$3.8M | — | — | — | — | — | — |
| Price / book | 0.7 | — | — | — | — | — | — |
| Earnings yield | −213.4% | — | — | — | — | — | — |
| Free cash flow yield | −181.9% | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.49 | $16.28 | $76.60 | $79.60 | $86.42 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | — | — | — | — | — | — |
| Earnings per share | −$5.31 | — | — | — | — | — | — |
| Operating cash flow per share | −$4.53 | — | — | — | — | — | — |
| Free cash flow per share | −$4.53 | — | — | — | — | — | — |
| Cash per share | $5.04 | — | — | — | — | — | — |
| Book value per share | $3.51 | — | — | — | — | — | — |
| Tangible book value per share | $3.51 | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — |
| Shares outstanding | 1.5M | — | — | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −270.8% | −534.0% | −243.3% | −122.6% | −167.8% | −261.3% | −723.5% |
| Return on assets (ROA) | −138.0% | −243.8% | −170.6% | −106.9% | −153.9% | −159.8% | −234.3% |
| Return on tangible assets | −103.6% | −365.6% | −189.1% | −129.0% | −95.7% | −142.7% | −234.3% |
| Financial health | |||||||
| Total debt | — | — | — | — | — | $66,503 | — |
| Cash & short-term investments | $7.6M | $3.7M | $7.5M | $9.1M | $13.0M | $3.2M | $2.5M |
| Net debt | −$7.6M | −$3.7M | −$7.5M | −$9.1M | −$13.0M | −$3.1M | −$2.5M |
| Debt / equity | — | — | — | — | — | 0.02 | — |
| Debt / assets | — | — | — | — | — | 0.02 | — |
| Net debt / EBITDA | — | −184.19 | — | — | — | — | — |
| Current ratio | 3.18 | 1.19 | 2.53 | 4.55 | 15.71 | 6.82 | 1.48 |
| Quick ratio | 3.18 | 1.19 | 2.53 | 4.55 | 15.71 | 6.82 | 1.48 |
| Interest coverage | — | — | — | — | -193.7 | — | — |
| Working capital | $5.3M | $615,121 | $4.7M | $7.3M | $12.4M | $2.8M | $819,854 |
| Invested capital | −$2.3M | −$3.1M | −$2.8M | −$1.8M | −$548,605 | −$407,322 | −$1.7M |
| Tangible asset value | $5.3M | $615,121 | $4.7M | $7.3M | $12.4M | $2.7M | $819,854 |
| Net current asset value | $5.3M | $615,121 | $4.7M | $7.3M | $12.4M | $2.7M | $819,854 |
| Graham net-net per share | $3.45 | — | — | — | — | — | — |
| Capital allocation | |||||||
| Share buybacks (net) | $1,040 | $0 | — | — | — | — | — |
| Capex / depreciation | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | |||||||
| Receivables turnover | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $49,772 | $90,143 | $129,159 | — | — | — | — |
| Average payables | — | — | $16,674 | $46,456 | $63,374 | — | $2,304 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ACXP's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ACXP valuation and financial ratios
Acurx Pharmaceuticals earned a return on equity of −270.8% in fiscal 2025. It returned $0.0 million to shareholders: $0 in dividends and $0.0 million in share buybacks.
See the ACXP income statement, the ACXP chart for price history, or the ACXP stock overview for the latest quote and news.
ACXP key metrics FAQ
What is Acurx Pharmaceuticals's return on equity?
Acurx Pharmaceuticals's return on equity (ROE) was −270.8% in fiscal 2025: net income of -$8.0 million on average shareholders' equity of $2.9 million.
Does Acurx Pharmaceuticals buy back its shares?
Yes. Acurx Pharmaceuticals spent $0.0 million on net share repurchases in fiscal 2025.
What is Acurx Pharmaceuticals's free cash flow yield?
Acurx Pharmaceuticals generated -$6.8 million of free cash flow in fiscal 2025, a free cash flow yield of −181.9% on its market value at year-end ($3.7 million).
What is Acurx Pharmaceuticals's current ratio?
Acurx Pharmaceuticals's current ratio was 3.18 at the end of fiscal 2025: current assets were 3.18 times current liabilities.